Bristol Myers Squibb

-12.98%

Live  

Bristol Myers Squibb is a global biopharmaceutical company that focuses on discovering, developing, and delivering innovative treatments for patients with serious and life-threatening diseases. The company was founded in 1887 and is headquartered in New York City, United States. Bristol Myers Squibb has a strong presence in the United States, with operations and facilities in over 70 countries around the world.
Bristol Myers Squibb is committed to improving patient outcomes by leveraging its scientific expertise and resources to advance the development of new treatments. The company's research and development efforts focus on a variety of therapeutic areas, including oncology, cardiovascular diseases, immunology, and neuroscience.
In addition to its research and development efforts, Bristol Myers Squibb also has a strong commitment to corporate responsibility and sustainability. The company has implemented various initiatives to support access to healthcare in underserved communities, reduce its environmental impact, and promote diversity and inclusion in the workplace.
Bristol Myers Squibb is also dedicated to collaborating with healthcare providers, patient organizations, and other stakeholders to improve patient care and treatment outcomes. The company works closely with these partners to develop educational programs, advocate for policy changes, and support patient advocacy initiatives.
Overall, Bristol Myers Squibb's mission is to use its resources and expertise to create and deliver innovative medicines that help patients live better, healthier lives.

Bristol Myers Squibb is a big company that helps people stay healthy by making medicines. They focus mainly on treating serious illnesses like cancer, heart problems, and other tough diseases. Think of them like a team of inventors and scientists who work together to find new ways to help people feel better.
The company makes money by selling the medicines they create. When they discover a new medicine that works well, they can sell it to hospitals and pharmacies. Doctors give these medicines to patients who need them, and the company earns money from every medicine sold. Sometimes they even work with other companies to develop new drugs, which can also bring in money.
Bristol Myers Squibb is successful for a few reasons. First, they invest a lot of time and money into research to find new treatments. This means they are often the first to discover new and effective medicines. Second, many of their drugs help with very serious conditions that need better treatments, so there is always a high demand for what they provide.
Looking into the future, they will likely continue to be successful because new diseases keep appearing, and people always need better ways to stay healthy. Plus, they are good at working with other scientists and companies, which can help them create even more helpful medicines. As long as there are health problems to solve, Bristol Myers Squibb will have a big role in finding solutions and helping people live better lives.

MS4gR2xvYm FsIFByZXNl bmNlOiBCcm lzdG9sIE15 ZXJzIFNxdW liYiBvcGVy YXRlcyBpbi Btb3JlIHRo YW4gNjAgY2 91bnRyaWVz IGFuZCBoYX MgYSBzdHJv bmcgZ2xvYm FsIHByZXNl bmNlLiBUaG lzIGFsbG93 cyB0aGUgY2 9tcGFueSB0 byBjYXRlci B0byBhIGRp dmVyc2UgY3 VzdG9tZXIg YmFzZSBhbm QgZXhwYW5k IGludG8gZW 1lcmdpbmcg bWFya2V0cy 48YnI+Mi4g U3Ryb25nIF BvcnRmb2xp bzogVGhlIG NvbXBhbnkg aGFzIGEgZG l2ZXJzaWZp ZWQgcG9ydG ZvbGlvIG9m IHBoYXJtYW NldXRpY2Fs cywgaW5jbH VkaW5nIG1l ZGljaW5lcy Bmb3Igb25j b2xvZ3ksIG ltbXVub2xv Z3ksIGNhcm Rpb3Zhc2N1 bGFyIGRpc2 Vhc2VzLCBh bmQgb3RoZX IgdGhlcmFw ZXV0aWMgYX JlYXMuIEl0 cyBwcm9kdW N0cyBoYXZl IGJlZW4gdX NlZCBieSBt aWxsaW9ucy BvZiBwYXRp ZW50cyB3b3 JsZHdpZGUu PGJyPjMuIE ZvY3VzIG9u IFJlc2Vhcm NoIGFuZCBE ZXZlbG9wbW VudDogQnJp c3RvbCBNeW VycyBTcXVp YmIgaW52ZX N0cyBoZWF2 aWx5IGluIH Jlc2VhcmNo IGFuZCBkZX ZlbG9wbWVu dCwgd2l0aC BhIGZvY3Vz IG9uIGRldm Vsb3Bpbmcg aW5ub3ZhdG l2ZSBtZWRp Y2luZXMgdG 8gYWRkcmVz cyB1bm1ldC BtZWRpY2Fs IG5lZWRzLi BJdCBoYXMg YSByb2J1c3 QgcGlwZWxp bmUgb2YgcG 90ZW50aWFs IHRyZWF0bW VudHMgZm9y IGEgcmFuZ2 Ugb2YgZGlz ZWFzZXMuPG JyPjQuIENv bGxhYm9yYX RpdmUgUGFy dG5lcnNoaX BzOiBUaGUg Y29tcGFueS BoYXMgZm9y bWVkIHN0cm F0ZWdpYyBw YXJ0bmVyc2 hpcHMgd2l0 aCBvdGhlci BwaGFybWFj ZXV0aWNhbC Bjb21wYW5p ZXMsIGFjYW RlbWljIGlu c3RpdHV0aW 9ucywgYW5k IHJlc2Vhcm NoIG9yZ2Fu aXphdGlvbn MgdG8gZHJp dmUgaW5ub3 ZhdGlvbiBh bmQgZGV2ZW xvcCBuZXcg dGhlcmFwaW VzLjxicj41 LiBDb21taX RtZW50IHRv IFBhdGllbn QgQWNjZXNz OiBCcmlzdG 9sIE15ZXJz IFNxdWliYi BpcyBjb21t aXR0ZWQgdG 8gaW1wcm92 aW5nIGFjY2 VzcyB0byBo ZWFsdGhjYX JlIGZvciBw YXRpZW50cy Bhcm91bmQg dGhlIHdvcm xkLiBUaGUg Y29tcGFueS BoYXMgdmFy aW91cyBpbm l0aWF0aXZl cywgc3VjaC BhcyBwYXRp ZW50IGFzc2 lzdGFuY2Ug cHJvZ3JhbX MsIHRvIGhl bHAgcGF0aW VudHMgaW4g bmVlZCBhY2 Nlc3MgdGhl aXIgbWVkaW NpbmVzLjxi cj42LiBDb3 Jwb3JhdGUg U29jaWFsIF Jlc3BvbnNp YmlsaXR5Oi BUaGUgY29t cGFueSBpcy Bjb21taXR0 ZWQgdG8gbW FraW5nIGEg cG9zaXRpdm UgaW1wYWN0 IG9uIHNvY2 lldHkgdGhy b3VnaCBpdH MgY29ycG9y YXRlIHNvY2 lhbCByZXNw b25zaWJpbG l0eSBpbml0 aWF0aXZlcy 4gVGhpcyBp bmNsdWRlcy Bpbml0aWF0 aXZlcyByZW xhdGVkIHRv IGVudmlyb2 5tZW50YWwg c3VzdGFpbm FiaWxpdHks IHBhdGllbn QgZWR1Y2F0 aW9uLCBhbm QgY29tbXVu aXR5IG91dH JlYWNoIHBy b2dyYW1zLj xicj43LiBT dHJvbmcgRm luYW5jaWFs IFBlcmZvcm 1hbmNlOiBC cmlzdG9sIE 15ZXJzIFNx dWliYiBoYX MgYSBzdHJv bmcgdHJhY2 sgcmVjb3Jk IG9mIGZpbm FuY2lhbCBw ZXJmb3JtYW 5jZSwgd2l0 aCBjb25zaX N0ZW50IHJl dmVudWUgZ3 Jvd3RoIGFu ZCBhIHN0cm 9uZyBiYWxh bmNlIHNoZW V0LiBUaGlz IHN0YWJpbG l0eSBhbGxv d3MgdGhlIG NvbXBhbnkg dG8gY29udG ludWUgaW52 ZXN0aW5nIG luIHJlc2Vh cmNoIGFuZC BkZXZlbG9w bWVudCBhbm QgcHVyc3Vl IHN0cmF0ZW dpYyBvcHBv cnR1bml0aW VzLjxicj44 LiBDdWx0dX JlIG9mIERp dmVyc2l0eS BhbmQgSW5j bHVzaW9uOi BUaGUgY29t cGFueSBoYX MgYSBzdHJv bmcgY3VsdH VyZSBvZiBk aXZlcnNpdH kgYW5kIGlu Y2x1c2lvbi wgd2l0aCBh IHdvcmtmb3 JjZSB0aGF0 IGlzIHJlZm xlY3RpdmUg b2YgdGhlIG dsb2JhbCBj b21tdW5pdG llcyBpdCBz ZXJ2ZXMuIF RoaXMgaGVs cHMgZHJpdm UgY3JlYXRp dml0eSwgaW 5ub3ZhdGlv biwgYW5kIG EgZGVlcCB1 bmRlcnN0YW 5kaW5nIG9m IGRpZmZlcm VudCBwYXRp ZW50IG5lZW RzLjxicj45 LiBTdHJvbm cgTGVhZGVy c2hpcDogQn Jpc3RvbCBN eWVycyBTcX VpYmIgaGFz IGEgaGlnaG x5IGV4cGVy aWVuY2VkIG FuZCBkZWRp Y2F0ZWQgbG VhZGVyc2hp cCB0ZWFtLC B3aXRoIGEg dHJhY2sgcm Vjb3JkIG9m IGRyaXZpbm cgZ3Jvd3Ro IGFuZCBpbm 5vdmF0aW9u LiBUaGlzIH Byb3ZpZGVz IGEgc3Ryb2 5nIGZvdW5k YXRpb24gZm 9yIHRoZSBj b21wYW55J3 Mgc3VjY2Vz cy48YnI+MT AuIFJlY29n bml0aW9uIG FuZCBBd2Fy ZHM6IFRoZS Bjb21wYW55 J3MgZWZmb3 J0cyBpbiBy ZXNlYXJjaC BhbmQgZGV2 ZWxvcG1lbn QsIHBhdGll bnQgYWNjZX NzLCBhbmQg Y29ycG9yYX RlIHNvY2lh bCByZXNwb2 5zaWJpbGl0 eSBoYXZlIG JlZW4gcmVj b2duaXplZC B0aHJvdWdo IHZhcmlvdX MgYXdhcmRz IGFuZCByZW NvZ25pdGlv biwgc3VjaC BhcyBiZWlu ZyByYW5rZW QgYW1vbmcg dGhlIHRvcC AxMDAgQmVz dCBDb3Jwb3 JhdGUgQ2l0 aXplbnMgYn kgQ29ycG9y YXRlIFJlc3 BvbnNpYmls aXR5IE1hZ2 F6aW5lLg==

QnJpc3RvbC BNeWVycyBT cXVpYmIgaX MgYSBnbG9i YWwgYmlvcG hhcm1hY2V1 dGljYWwgY2 9tcGFueSB0 aGF0IGZvY3 VzZXMgb24g ZGV2ZWxvcG luZyBhbmQg ZGVsaXZlcm luZyBpbm5v dmF0aXZlIG 1lZGljaW5l cyBmb3IgcG F0aWVudHMg d2l0aCBzZX Jpb3VzIGFu ZCBsaWZlLX RocmVhdGVu aW5nIGRpc2 Vhc2VzLiBU aGVpciBidX NpbmVzcyBt b2RlbCBpcy Bkcml2ZW4g YnkgdGhlaX IgY29tbWl0 bWVudCB0by BkaXNjb3Zl cmluZywgZG V2ZWxvcGlu ZywgYW5kIG RlbGl2ZXJp bmcgbGlmZS 1jaGFuZ2lu ZyB0cmVhdG 1lbnRzIGZv ciBwYXRpZW 50cyBhbmQg Y3JlYXRpbm cgbG9uZy10 ZXJtIHZhbH VlIGZvciB0 aGVpciBzdG FrZWhvbGRl cnMuPGJyPl RoZWlyIG1h aW4gYnVzaW 5lc3Mgc2Vn bWVudHMgaW 5jbHVkZTo8 YnI+MS4gSW 5ub3ZhdGl2 ZSBNZWRpY2 luZXM6IFRo aXMgc2VnbW VudCBmb2N1 c2VzIG9uIG RldmVsb3Bp bmcgYW5kIG NvbW1lcmNp YWxpemluZy BtZWRpY2lu ZXMgaW4gdm FyaW91cyB0 aGVyYXBldX RpYyBhcmVh cyBzdWNoIG FzIG9uY29s b2d5LCBjYX JkaW92YXNj dWxhciwgaW 1tdW5vc2Np ZW5jZSwgYW 5kIGZpYnJv c2lzLjxicj 4yLiBTcGVj aWFsdHkgTW VkaWNpbmVz OiBUaGlzIH NlZ21lbnQg Zm9jdXNlcy BvbiBkZXZl bG9waW5nIG FuZCBjb21t ZXJjaWFsaX ppbmcgbWVk aWNpbmVzIG ZvciByYXJl IGRpc2Vhc2 VzIGFuZCBk aXNvcmRlcn MsIGluY2x1 ZGluZyBoZW 1hdG9sb2d5 LCBpbW11bm 9sb2d5LCBh bmQgbmV1cm 9sb2d5Ljxi cj4zLiBFc3 RhYmxpc2hl ZCBNZWRpY2 luZXM6IFRo aXMgc2VnbW VudCBmb2N1 c2VzIG9uIH Byb3ZpZGlu ZyBwYXRpZW 50cyB3aXRo IGFjY2Vzcy B0byBoaWdo LXF1YWxpdH ksIGVzdGFi bGlzaGVkIG 1lZGljaW5l cyBhdCBhZm ZvcmRhYmxl IHByaWNlcy 48YnI+QnJp c3RvbCBNeW VycyBTcXVp YmIncyBidX NpbmVzcyBt b2RlbCByZW xpZXMgb24g dGhlaXIgYW JpbGl0eSB0 byBkaXNjb3 ZlciBhbmQg ZGV2ZWxvcC Bpbm5vdmF0 aXZlIG1lZG ljaW5lcyB0 aGF0IGFkZH Jlc3Mgc2ln bmlmaWNhbn QgdW5tZXQg bWVkaWNhbC BuZWVkcywg b2J0YWluIH JlZ3VsYXRv cnkgYXBwcm 92YWxzLCBh bmQgc3VjY2 Vzc2Z1bGx5 IGNvbW1lcm NpYWxpemUg dGhlc2UgbW VkaWNpbmVz IGdsb2JhbG x5LiBUaGV5 IGFsc28gaG F2ZSBwYXJ0 bmVyc2hpcH MgYW5kIGNv bGxhYm9yYX Rpb25zIHdp dGggb3RoZX IgYmlvcGhh cm1hY2V1dG ljYWwgY29t cGFuaWVzIH RvIGV4cGFu ZCB0aGVpci Bwb3J0Zm9s aW8gYW5kIH JlYWNoIG5l dyBtYXJrZX RzLjxicj5J biBhZGRpdG lvbiB0byB0 aGVpciBjb3 JlIGJ1c2lu ZXNzLCBCcm lzdG9sIE15 ZXJzIFNxdW liYiBhbHNv IGhhcyBhIH N0cm9uZyBm b2N1cyBvbi BzdXN0YWlu YWJpbGl0eS BhbmQgY29y cG9yYXRlIH Jlc3BvbnNp YmlsaXR5Li BUaGV5IGFp bSB0byBpbX Byb3ZlIGhl YWx0aCBvdX Rjb21lcywg cmVkdWNlIH RoZWlyIGVu dmlyb25tZW 50YWwgaW1w YWN0LCBhbm Qgc3VwcG9y dCB0aGUgY2 9tbXVuaXRp ZXMgd2hlcm UgdGhleSBv cGVyYXRlLj xicj5PdmVy YWxsLCB0aG VpciBidXNp bmVzcyBtb2 RlbCBpcyBj ZW50ZXJlZC Bhcm91bmQg YnJpbmdpbm cgbGlmZS1z YXZpbmcgdH JlYXRtZW50 cyB0byBwYX RpZW50cywg Y3JlYXRpbm cgdmFsdWUg Zm9yIHRoZW lyIHNoYXJl aG9sZGVycy wgYW5kIGNv bnRyaWJ1dG luZyB0byBh IHN1c3RhaW 5hYmxlIGZ1 dHVyZS4=

AI could potentially influence Bristol Myers Squibb (BMS) in several ways, but the extent of the threat depends on various factors.
1. Substitution: AI has the potential to revolutionize drug discovery, development, and personalized medicine. Competitors or new entrants using advanced AI technologies could develop innovative therapies more quickly and at lower costs, potentially substituting BMS products. If AI-enabled companies succeed in creating effective alternatives or worsening the efficacy of existing drugs, this would pose a material threat to BMS’s market share.
2. Disintermediation: While BMS primarily operates in pharmaceuticals, advancements in AI-driven telemedicine and digital health platforms may change the landscape of how patients receive treatments and follow-up care. If such platforms increasingly bypass traditional pharmaceutical channels, BMS could face challenges in maintaining direct relationships with healthcare providers and patients, impacting its ability to effectively market its products.
3. Margin Pressure: The integration of AI in the pharmaceutical industry can lead to more efficient drug development processes, potentially driving down research and development costs. If competitors implement AI successfully and reduce their own costs, BMS may face margin pressure. Increased competition from companies leveraging AI to improve operational efficiencies could also affect pricing power in the market.
In conclusion, while AI presents opportunities for innovation, it also poses potential threats to BMS’s competitive positioning through these avenues. The company would need to proactively adapt to these changes by investing in AI technologies and strategic partnerships to mitigate associated risks.

Bristol Myers Squibb’s (BMS) earnings, cash flow, and valuation are influenced by interest rate changes in several ways.
1. Earnings: Changes in interest rates can affect BMS through several channels. For one, higher interest rates typically increase borrowing costs for companies with outstanding debt. If BMS has significant debt, higher interest expenses could reduce net income. Additionally, if higher rates dampen consumer spending, it could lead to lower demand for healthcare products, ultimately impacting sales and earnings.
2. Cash Flow: Rising interest rates may also affect BMS’s cash flow. Increased borrowing costs would lead to lower net cash flows from financing activities. Furthermore, if consumers and insurers cut back on spending due to higher rates, it could reduce cash inflows from sales. Conversely, if interest rates rise significantly, the company may see an uptick in investment income from cash or investments held.
3. Valuation: The valuation of BMS is closely related to discount rates used in financial models. When interest rates rise, the discount rate applied to future cash flows increases, which can lower the present value of those cash flows. This typically leads to a decrease in stock price, as investors may require a higher return on investment to compensate for increased risk associated with higher rates.
In summary, Bristol Myers Squibb’s earnings, cash flow, and valuation are sensitive to interest rate changes, primarily through the channels of financing costs, consumer behavior, and the discounting of future cash flows. The overall impact will depend on the magnitude of interest rate changes and the company’s financial strategies in response to those changes.

CiAgICAgIC AgICAgIDxk aXYgc3R5bG U9J3dpZHRo OiAxMDAlOy BkaXNwbGF5 OiBmbGV4Oy BqdXN0aWZ5 LWNvbnRlbn Q6IGNlbnRl cjsnPgogIC AgICAgICAg ICAgICAgPG RpdiBzdHls ZT0nCiAgIC AgICAgICAg ICAgICAgIC AgZGlzcGxh eTogZmxleD sKICAgICAg ICAgICAgIC AgICAgICBh bGlnbi1pdG VtczogY2Vu dGVyOwogIC AgICAgICAg ICAgICAgIC AgIGJhY2tn cm91bmQtY2 9sb3I6ICNm MGY0Zjg7Ci AgICAgICAg ICAgICAgIC AgICAgYm9y ZGVyOiAxcH ggc29saWQg I2QxZTNmMD sKICAgICAg ICAgICAgIC AgICAgICBi b3JkZXItcm FkaXVzOiAx MHB4OwogIC AgICAgICAg ICAgICAgIC AgIHBhZGRp bmc6IDEwcH g7CiAgICAg ICAgICAgIC AgICAgICAg bWFyZ2luOi AyMHB4IDA7 CiAgICAgIC AgICAgICAg ICAgICAgZm 9udC1mYW1p bHk6ICJTZW dvZSBVSSIs IFJvYm90by wgc2Fucy1z ZXJpZjsKIC AgICAgICAg ICAgICAgIC AgICBib3gt c2hhZG93Oi AwIDJweCA2 cHggcmdiYS gwLCAwLCAw LCAwLjA1KT sKICAgICAg ICAgICAgIC AgICAgICBt YXgtd2lkdG g6IDkwMHB4 OwogICAgIC AgICAgICAg ICAgICAgIH dpZHRoOiAx MDAlOyc+Cg ogICAgICAg ICAgICAgIC AgICAgIDxp bWcgc3JjPS Jhc3NldHMv bG9nb3Mvc2 xXTmhmN3Yz Q2VjVVo0dm 9pMlAud2Vi cCIgYWx0PS JCcmlzdG9s IE15ZXJzIF NxdWliYiIg dGl0bGU9Ik JyaXN0b2wg TXllcnMgU3 F1aWJiIiAg Y2xhc3M9Im ltZy1mbHVp ZCIgaGVpZ2 h0PTkwIHdp ZHRoPTkwIG xvYWRpbmc9 J2xhenknIH N0eWxlPSdi b3JkZXItcm FkaXVzOiA2 cHg7Jz4KCi AgICAgICAg ICAgICAgIC AgICAgPGRp diBzdHlsZT 0nZmxleDog MTsgdGV4dC 1hbGlnbjog Y2VudGVyOy BtYXJnaW4t bGVmdDogNX B4Oyc+CiAg ICAgICAgIC AgICAgICAg ICAgICAgID xwIHN0eWxl PSdmb250LX NpemU6IDI2 cHg7IGNvbG 9yOiAjMzMz OyBtYXJnaW 4tYm90dG9t OiAxNXB4Oy c+CiAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIC Dwn5OIIFdh bnQgdG8gcm VhZCBtb3Jl IGFib3V0IE JyaXN0b2wg TXllcnMgU3 F1aWJiPwog ICAgICAgIC AgICAgICAg ICAgICAgIC A8L3A+Cgog ICAgICAgIC AgICAgICAg ICAgICAgIC A8YSBocmVm PSdpbmRleC 5waHA/cGFn ZT1zaWdudX AnIHN0eWxl PScKICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg IGJhY2tncm 91bmQtY29s b3I6ICMwMD dCRkY7CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBjb2xv cjogI2ZmZj sKICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIH BhZGRpbmc6 IDEwcHggMj BweDsKICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIGJvcmRl ci1yYWRpdX M6IDVweDsK ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgIHRl eHQtZGVjb3 JhdGlvbjog bm9uZTsKIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgIGZvbn Qtd2VpZ2h0 OiBib2xkOw ogICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgbW FyZ2luLXJp Z2h0OiAxMH B4OwogICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgdHJhbnNp dGlvbjogYm Fja2dyb3Vu ZC1jb2xvci AwLjNzIGVh c2U7JwogIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgb25tb3 VzZW92ZXI9 J3RoaXMuc3 R5bGUuYmFj a2dyb3VuZE NvbG9yPSIj MDA1NmIzIi cKICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIG 9ubW91c2Vv dXQ9J3RoaX Muc3R5bGUu YmFja2dyb3 VuZENvbG9y PSIjMDA3Qk ZGIic+CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBTaWdu IHVwIGZvci BmcmVlCiAg ICAgICAgIC AgICAgICAg ICAgICAgID wvYT4KCiAg ICAgICAgIC AgICAgICAg ICAgICAgID xzcGFuIHN0 eWxlPSdtYX JnaW46IDAg OHB4OyBjb2 xvcjogIzU1 NTsnPm9yPC 9zcGFuPgoK ICAgICAgIC AgICAgICAg ICAgICAgIC AgPGEgaHJl Zj0naW5kZX gucGhwP3Bh Z2U9bG9naW 4nIHN0eWxl PScKICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg IGNvbG9yOi AjMDA3QkZG OwogICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg dGV4dC1kZW NvcmF0aW9u OiB1bmRlcm xpbmU7CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBmb250 LXdlaWdodD ogNTAwOyc+ CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBs b2cgaW4KIC AgICAgICAg ICAgICAgIC AgICAgICAg PC9hPgoKCi AgICAgICAg ICAgICAgIC AgICAgICAg IDxwIHN0eW xlPSdtYXJn aW4tdG9wOi AxNXB4OyBm b250LXNpem U6IDEzcHg7 IGZvbnQtd2 VpZ2h0OiBi b2xkOyBjb2 xvcjogI2Qz MmYyZjsnPg ogICAgICAg ICAgICAgIC AgICAgICAg ICAgICAg4p qhIEluc3Rh bnRseSBhY2 Nlc3MgPGk+ IlRoZSBDaG Vja2xpc3Qg VmFsdWUgSW 52ZXN0b3Ig 4oCUIEEgU2 1hcnRlciBX YXkgdG8gUG ljayBTdG9j a3MiPC9pPi DigJQgZnJl ZSEKICAgIC AgICAgICAg ICAgICAgIC AgICAgPC9w PgoKICAgIC AgICAgICAg ICAgICAgIC AgICAgPCEt LQogICAgIC AgICAgICAg ICAgICAgIC AgICA8ZGl2 IHN0eWxlPS dtYXJnaW4t dG9wOiAxMn B4OyBmb250 LXNpemU6ID EzcHg7IGNv bG9yOiAjND Q0Oyc+CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBTaWdu IHVwIG5vdy BhbmQgZ2V0 IG91ciBmcm VlIGVCb29r IAogICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg PGI+VGhlIE NoZWNrbGlz dCBWYWx1ZS BJbnZlc3Rv ciDigJQgQS BTbWFydGVy IFdheSB0by BQaWNrIFN0 b2NrczwvYj 4KICAgICAg ICAgICAgIC AgICAgICAg ICAgPC9kaX Y+CiAgICAg ICAgICAgIC AgICAgICAg ICAgIC0tPg ogICAgICAg ICAgICAgIC AgICAgICAg ICA8IS0tCi AgICAgICAg ICAgICAgIC AgICAgICAg IDxkaXYgc3 R5bGU9J21h cmdpbi10b3 A6IDE2cHg7 IGZvbnQtc2 l6ZTogMTRw eDsgY29sb3 I6ICM0NDQ7 IGZvbnQtZm FtaWx5OiAt YXBwbGUtc3 lzdGVtLCBC bGlua01hY1 N5c3RlbUZv bnQsIFNlZ2 9lIFVJLCBS b2JvdG8sIE hlbHZldGlj YSBOZXVlLC BzYW5zLXNl cmlmOyBsaW 5lLWhlaWdo dDogMS42Oy c+CiAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIC BIYXZlIHlv dSBoZWFyZC BhYm91dCBv dXIgc2hvcn QgPHN0cm9u ZyBzdHlsZT 0nZm9udC13 ZWlnaHQ6ID YwMDsnPkRh aWx5IFZpZG VvIE5ld3Ns ZXR0ZXI8L3 N0cm9uZz4/ CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICA8 YSBocmVmPS dodHRwczov L3d3dy5pbn NpZ2h0ZnVs dmFsdWUuY2 9tL25ld3Ns ZXR0ZXIucG hwJyB0YXJn ZXQ9J19ibG Fuaycgc3R5 bGU9J2NvbG 9yOiAjMDA3 QkZGOyB0ZX h0LWRlY29y YXRpb246IG 5vbmU7IGZv bnQtd2VpZ2 h0OiA1MDA7 IG1hcmdpbi 1sZWZ0OiA2 cHg7Jz4KIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIC BGaW5kIG91 dCBtb3JlCi AgICAgICAg ICAgICAgIC AgICAgICAg ICAgICA8L2 E+CiAgICAg ICAgICAgIC AgICAgICAg ICAgIDwvZG l2PgogICAg ICAgICAgIC AgICAgICAg ICAgICAtLT 4KICAgICAg ICAgICAgIC AgICAgICA8 L2Rpdj4KIC AgICAgICAg ICAgICAgID wvZGl2Pgog ICAgICAgIC AgICA8L2Rp dj4KICAgIC AgICAgICAg CiAgICAgIC AgCiAgICAg ICAgPHNwYW 4gY2xhc3M9 J2JsdXJyZW QtdGV4dCc+ CiAgICAgIC AgICAgIE1T NGdRbkpwYz MgUnZiQ0JO ZVdWeSBjeU JUY1hWcFlt IElnZDJGek lHWnYgZFc1 a1pXUWdhVy A0Z01UZzRO eUJpIGVTQl hhV3hzYVcg RnRJRTFqVE dGeSBaVzRn UW5KcGMzIF J2YkNCaGJt UWcgU205b2 JpQlNhWCBC c1pYa2dUWG xsIGNuTWdZ WE1nWVMgQn dhR0Z5YldG aiBaWFYwYV dOaGJDIEJq YjIxd1lXNT UgSUdsdUlF TnNhVyA1MG IyNHNJRTVs IGR5QlpiM0 pyTGogeGlj ajR5TGlCVS BhR1VnWTI5 dGNHIEZ1ZV NCaVpXTmgg YldVZ2EyNX ZkMiA0Z1lY TWdRbkpwIG MzUnZiQ0JO ZVcgVnljeU JEYjIxdyBZ VzU1SUdsdU lEIEU1TURB Z1lXNWsgSU cxbGNtZGxa QyBCM2FYUm 9JRTFCIElF Tm9aWE5sWW 4gSnZkV2Rv SUUxaCBibl ZtWVdOMGRY IEpwYm1jZ1 EyOXQgY0dG dWVTQjBieS BCbWIzSnRJ RUp5IGFYTj BiMnd0VFgg bGxjbk1nUT I5eSBjRzl5 WVhScGIyID RnYVc0Z01U azEgT0M0OF luSStNeSA0 Z1NXNGdNVG s0IE9Td2dR bkpwYzMgUn ZiQzFOZVdW eSBjeUJEYj NKd2IzIEpo ZEdsdmJpQn QgWlhKblpX UWdkMiBsMG FDQlRjWFZw IFltSWdRMj l5Y0cgOXlZ WFJwYjI0Zy BkRzhnWW1W amIyIDFsSU hSb1pTQncg Y21WelpXNT BMVyBSaGVT QkNjbWx6IG RHOXNMVTE1 WlggSnpJRk 54ZFdsaSBZ aUJEYjIxd1 lXIDU1TGp4 aWNqNDAgTG lCQ2NtbHpk RyA5c0lFMT VaWEp6IElG TnhkV2xpWW kgQnBjeUJq ZFhKeSBaVz UwYkhrZ2Nt IEZ1YTJWa0 lHRnogSUc5 dVpTQnZaaS BCMGFHVWdk Rzl3IElESX dJR3hoY20g ZGxjM1FnY0 doaCBjbTFo WTJWMWRHIG xqWVd3Z1ky OXQgY0dGdW FXVnpJRyBs dUlIUm9aU0 IzIGIzSnNa QzQ4WW4gSS tOUzRnVkdo bCBJR052Yl hCaGJuIGtn YUdGeklHRW cgYzNSeWIy NW5JRyBadl kzVnpJRzl1 IElISmxjMl ZoY20gTm9J R0Z1WkNCay BaWFpsYkc5 d2JXIFZ1ZE N3Z2QybDAg YUNCdmRtVn lJRCBRc01E QXdJSE5qIG FXVnVkR2x6 ZEggTWdkMj l5YTJsdSBa eUJ2YmlCMl lYIEpwYjNW eklHUnkgZF djZ1pHbHpZ MiA5MlpYSj VJR0Z1IFpD QmtaWFpsYk cgOXdiV1Z1 ZENCdyBjbT lxWldOMGN5 IDQ4WW5JK0 5pNGcgUW5K cGMzUnZiQy BCTmVXVnlj eUJUIGNYVn BZbUlnYUcg RnpJR0VnWk dsMiBaWEp6 WlNCd2IzIE owWm05c2FX OGcgYjJZZ1 pISjFaMyBN Z2MzQmhibT VwIGJtY2di WFZzZEcgbH diR1VnZEdo bCBjbUZ3Wl hWMGFXIE1n WVhKbFlYTX MgSUdsdVky eDFaRyBsdV p5QmpZWEpr IGFXOTJZWE 5qZFcgeGhj aXdnYjI1ai BiMnh2WjNr c0lHIGx0Yl hWdWIyeHYg WjNrc0lHRn VaQyBCdVpY VnliM05qIG FXVnVZMlV1 UEcgSnlQam N1SUZSbyBa U0JqYjIxd1 lXIDU1SUdo aGN5QmggSU hCeVpYTmxi bSBObElHbH VJRzkyIFpY SWdOakFnWT IgOTFiblJ5 YVdWeiBJR0 Z1WkNCdFlY IEpyWlhSek lHbDAgY3lC d2NtOWtkVy BOMGN5QnBi aUJ2IGRtVn lJREUxTUMg QmpiM1Z1ZE hKcCBaWE1n ZDI5eWJHIF IzYVdSbExq eGkgY2o0NE xpQkNjbSBs emRHOXNJRT E1IFpYSnpJ Rk54ZFcgbG lZaUJvWVhN ZyBZU0JzYj I1bklHIGhw YzNSdmNua2 cgYjJZZ1ky OXNiRyBGaW IzSmhkR2x2 IGJpQmhibV FnY0cgRnlk RzVsY25Oby BhWEJ6SUhk cGRHIGdnYj NSb1pYSWcg Y0doaGNtMW hZMiBWMWRH bGpZV3dnIF kyOXRjR0Z1 YVcgVnpMQ0 JoWTJGayBa VzFwWXlCcG JuIE4wYVhS MWRHbHYgYm 5Nc0lHRnVa QyBCeVpYTm xZWEpqIGFD QnZjbWRoYm 0gbDZZWFJw YjI1eiBJSF J2SUdGa2Rt IEZ1WTJVZ1 pISjEgWnlC a2FYTmpiMy BabGNua2dZ VzVrIElHUm xkbVZzYjMg QnRaVzUwTG p4aSBjajQ1 TGlCVWFHIF VnWTI5dGNH RnUgZVNCb1 lYTWdZbSBW bGJpQnlaV0 52IFoyNXBl bVZrSUcgWn ZjaUJwZEhN ZyBaV1ptYj NKMGN5IEJw YmlCemRYTj AgWVdsdVlX SnBiRyBsMG VTQmhibVFn IGNtVnpjRz l1YzIgbGlh V3hwZEhrcy BJSEpoYm10 cGJtIGNnYj I0Z2RHaGwg SUVSdmR5Qk tiMiA1bGN5 QlRkWE4wIF lXbHVZV0pw YkcgbDBlU0 JKYm1SbCBl Q0JtYjNJZ0 1UIGdnWTI5 dWMyVmogZF hScGRtVWdl VyBWaGNuTX VQR0p5IFBq RXdMaUJDY2 0gbHpkRzlz SUUxNSBaWE p6SUZOeGRX IGxpWWlCb1 lYTWcgWVNC emRISnZibS BjZ1ptOWpk WE1nIGIyNG daR2wyWlgg SnphWFI1SU dGdSBaQ0Jw Ym1Oc2RYIE 5wYjI0c0lI ZHAgZEdnZ2 FXNXBkRyBs aGRHbDJaWE 1nIGRHOGdj M1Z3Y0cgOX lkQ0IxYm1S bCBjbkpsY0 hKbGMyIFZ1 ZEdWa0lHZH kgYjNWd2N5 QnBiaSBCMG FHVWdkMjl5 IGEzQnNZV0 5sSUcgRnVa Q0JwYmlCMC BhR1VnWTI5 dGJYIFZ1YV hScFpYTWcg YVhRZ2MyVn lkbSBWekxq eGljajR4IE 1TNGdWR2hs SUcgTnZiWE JoYm5rZyBh WE1nWVd4em J5IEJqYjIx dGFYUjAgWl dRZ2RHOGdZ MiA5eWNHOX lZWFJsIElI TnZZMmxoYk MgQnlaWE53 YjI1eiBhV0 pwYkdsMGVT IEJoYm1RZ2 FHRnogSUha aGNtbHZkWC BNZ2FXNXBk R2xoIGRHbD JaWE1nWm0g OWpkWE5sWk NCdiBiaUJw YlhCeWIzIF pwYm1jZ1lX TmogWlhOek lIUnZJRyAx bFpHbGphVz VsIGN5Qmhi bVFnYUcgVm hiSFJvWTJG eSBaU0JwYm lCMWJtIFJs Y25ObGNuWm wgWkNCamIy MXRkVyA1cG RHbGxjeTQ4 IFluSStNVE l1SUUgbHVJ REl3TWpBcy BJRUp5YVhO MGIyIHdnVF hsbGNuTWcg VTNGMWFXSm lJRyBGdWJt OTFibU5sIF pDQnBkSE1n WVcgTnhkV2 x6YVhScCBi MjRnYjJZZ1 lXIDV2ZEdo bGNpQncgYU dGeWJXRmpa WCBWMGFXTm hiQ0JqIGIy MXdZVzU1TE MgQkRaV3hu Wlc1bCBMQ0 JtYjNJZ0pE IGMwSUdKcG JHeHAgYjI0 c0lHMWhhMi BsdVp5QnBk Q0J2IGJtVW diMllnZEcg aGxJR3hoY2 1kbCBjM1Fn YldWeVoyIF Z5Y3lCcGJp QjAgYUdVZ2 NHaGhjbSAx aFkyVjFkR2 xqIFlXd2dh VzVrZFggTj Bjbmt1UEdK eSBQakV6TG lCVWFHIFVn YUdWaFpIRj EgWVhKMFpY SnpJRyA5bU lFSnlhWE4w IGIyd2dUWG xsY24gTWdV M0YxYVdKaS BJR2x6SUd4 dlkyIEYwWl dRZ2FXNGcg VG1WM0lGbH ZjbSBzZ1Ey bDBlU3dnIF luVjBJSFJv WlMgQmpiMj F3WVc1NSBJ R0ZzYzI4Z2 FHIEZ6SUhO cFoyNXAgWm 1sallXNTBJ RyA5d1pYSm hkR2x2IGJu TWdZVzVrSU cgWmhZMmxz YVhScCBaWE 1nYVc0Z2Iz IFJvWlhJZ2 JHOWogWVhS cGIyNXpJRy BGeWIzVnVa Q0IwIGFHVW dkMjl5Ykcg UXNJR2x1WT J4MSBaR2x1 WnlCUWNtIG x1WTJWMGIy NHMgSUU1bG R5QktaWCBK elpYa2dZVz VrIElGUmhi WEJoTEMgQk diRzl5YVdS aCBJR2x1SU hSb1pTIEJW Ym1sMFpXUW cgVTNSaGRH VnpMaiB4aW NqNHhOQzRn IFFYTWdiMl lnTWogQXlN Q3dnUW5KcC BjM1J2YkNC TmVXIFZ5Y3 lCVGNYVnAg WW1JZ2FHRm tJRyBGdUlH VnRjR3h2IG VXVmxJR052 ZFcgNTBJRz ltSUc5MiBa WElnTXpBc0 1EIEF3SUhC bGIzQnMgWl NCbmJHOWlZ VyB4c2VTND 0KICAgICAg ICA8L3NwYW 4+CiAgICAg ICAgCiAgIC AgICAg